Newron Pharmaceuticals SpA
NWRN
Company Profile
Business description
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
Contact
Via Antonio Meucci 3
Bresso
Milan20091
ITAT: +39 26103461
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
23
Stocks News & Analysis
stocks
Tesla: Shares down despite record deliveries
We think the positive third-quarter numbers will be largely offset by a weak fourth quarter.
stocks
ASX listed share dominates their industry
Shares are currently fairly valued with a Wide Moat rating.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,288.10 | 53.60 | 0.58% |
| CAC 40 | 8,081.54 | 24.91 | 0.31% |
| DAX 40 | 24,378.80 | 43.76 | -0.18% |
| Dow JONES (US) | 46,803.51 | 283.79 | 0.61% |
| FTSE 100 | 9,491.25 | 63.52 | 0.67% |
| HKSE | 27,140.92 | 146.20 | -0.54% |
| NASDAQ | 22,785.17 | 58.88 | -0.26% |
| Nikkei 225 | 45,769.50 | 832.77 | 1.85% |
| NZX 50 Index | 13,514.09 | 62.33 | 0.46% |
| S&P 500 | 6,720.34 | 4.99 | 0.07% |
| S&P/ASX 200 | 8,987.40 | 50.80 | 0.57% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |